ga naar hoofdinhoud
Vademecum Gynaecologische tumoren Ovariumcarcinoom Literatuur en richtlijnen

Literatuur

  1. Lawrie TA et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane database of systemic reviews. 2015; (12):CD004706
  2. Du Bois A et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute 2003; 95(17):1320- 1329
  3. Ozols RF et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194-3200
  4. Van Driel et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378:230-240
  5. Vergote I et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53
  6. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34-43
  7. Marchetti et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: a meta-analysis. Critical reviews in oncology / hematology 2019; vol 136 p64–69
  8. K. Moore et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379:2495-505
  9. Williams C et al. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010 (3):CD001034
  10. Pfisterer J et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24:4699-4707
  11. Aghajanian C et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039-2045
  12. Wagner U et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Brit J Cancer 2012; 107(4):588-591
  13. EMA recommends extenstion of indications for rucaparib. Nieuwsbericht website ESMO d.d. 18-12-2018 
  14. Mirza MR et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375(22):2154-64
  15. Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(9):1274-84
  16. Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390(10106):1949-61
  17. Pujade-Loraine E et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32:1302-1308
  18. Gibson JM et al. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. The Oncologist 2013; 18:1022-1031
  19. Van der Burg ME et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistent ovarian cancer. Eur J Cancer 2013; 49(6):1254-63
  20. Markman M et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jun; 101(3):436-40
  21. Mutch DG et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25(9):2811-8
  22. Fruscella E et al. Gemcitabine: current role and future options in the treatment of ovarian cancer. Crit Rev Oncol Hematol 2003; 48(1):81-88
  23. Gordon et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. JCO 2001; 3312-3322
  24. Sehouli et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011 Jan 10; 29(2):242-8
  25. David M et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35:1103-1111
  26. Vasey PA et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Instit 2004; 96:1682-91
  27. De Jongh FE et al. Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur Journal Cancer 2002; 38:2003-2015
  28. González-Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019 Dec 19; 381(25):2391-2402

Commissie BOM adviezen

Ga naar de commissie BOM adviezen over ovariumcarcinoom.

Richtlijnen

Ga naar de richtlijn Epitheliaal ovariumcarcinoom in de FMS richtlijnen­database.

Ga naar de richtlijn Erfelijk en familiair ovariumcarcinoom in de FMS richtlijnen­database.

Ga naar de richtlijn Ovarium/tubacarcinoom van VKGN - StOET.